A. Robinson

L. Sutherland, Ke Wang, A. Robinson, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada

Kelvin K. W. Chan, A. Robinson, J. Beca, 2021, BMC Cancer.

Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study.

S. Gupta, Philippe Bédard, M. Raphael, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy.

W. Hopman, A. Robinson, A. Kartolo, 2020, Immunotherapy.

Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.

E. Eisenhauer, C. Booth, A. Robinson, 2014, European journal of cancer.

A review of the use of exemestane in early breast cancer

A. Robinson, 2008, Therapeutics and clinical risk management.

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

A. Mansfield, R. Herbst, T. Mok, 2021, JTO clinical and research reports.

A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.

H. Feilotter, W. Hopman, A. Robinson, 2021, Cancer treatment and research communications.

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407.

A. Tafreshi, Ying Cheng, B. Halmos, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature.

E. Eisenhauer, M. Brundage, M. Raphael, 2019, JAMA oncology.

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.

A. Tafreshi, M. Pietanza, M. O'Brien, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis

D. Berman, F. Vera-Badillo, C. Booth, 2020, European urology open science.

Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens

L. Seymour, G. Nicholas, D. Tu, 2018, Investigational New Drugs.

Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease.

E. Yorida, K. Gelmon, S. Ellard, 2006, Clinical breast cancer.

A rare and unusual cause of mammographic calcification in the breast

A. Shaaban, A. Robinson, 2016, Journal of Clinical Pathology.

Abstract 1774: Progression-free survival curves suggest a dichotomous determinant of PD-L1 inhibitor efficacy

D. Bossé, A. Robinson, D. Stewart, 2017 .

PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024

A. Tafreshi, M. O'Brien, J. Brahmer, 2017 .

A Comparison of Hypofractionated and Twice-Daily Thoracic Irradiation in Limited-Stage Small-Cell Lung Cancer: An Overlap-Weighted Analysis

E. Stuart, A. Bezjak, A. Hope, 2021, Cancers.

Surgery after chemoradiotherapy in patients with stage III (N2 or N3, excluding T4) non-small-cell lung cancer: a systematic review.

C. Simone, Y. Ung, P. Ellis, 2019, Current oncology.

Causes of death and subsequent treatment after initial radical or palliative therapy of stage III non-small-cell lung cancer.

A. Robinson, K. Balchin, A. Ashworth, 2015, Current oncology.

A. Tafreshi, M. O'Brien, J. Brahmer, 2017, The Lancet. Oncology.

Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review

B. Hutton, M. Clemons, D. Fergusson, 2018, Breast cancer research and treatment.

A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer

B. Hutton, M. Clemons, S. Gertler, 2018, Breast Cancer Research and Treatment.

A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer

B. Hutton, M. Clemons, D. Fergusson, 2020, Supportive Care in Cancer.

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

J. Riess, V. Sinha, K. Mayawala, 2018, Clinical Cancer Research.

Reasons for palliative treatments in stage III non-small-cell lung cancer: what contribution is made by time-dependent changes in tumour or patient status?

A. Robinson, K. Balchin, A. Ashworth, 2015, Current oncology.

A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting

G. Dranitsaris, B. Hutton, M. Clemons, 2020, Breast.

Is cancer stage data missing completely at random? A report from a large population-based cohort of non-small cell lung cancer

C. Goldie, A. Robinson, T. Hanna, 2023, Frontiers in Oncology.

Should National Institute for Clinical Excellence (NICE) Guidelines Remove Urine Cytology as a Suggested Adjunct in Suspected Bladder Cancer (haematuria) Investigations?

A. Robinson, L. Gommersall, M. Kitchen, 2021, Journal of Endoluminal Endourology.

Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042

A. Mansfield, R. Herbst, T. Mok, 2019, Annals of Oncology.

OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%

A. Tafreshi, M. Pietanza, M. O'Brien, 2017 .

Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practice.

E. Eisenhauer, C. Booth, A. Robinson, 2014, European journal of cancer.

Risk of COVID-19 in Patients With Cancer.

B. Gyawali, C. Booth, A. Robinson, 2020, JAMA oncology.

MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC

Ying Cheng, B. Halmos, L. Paz-Ares, 2018, Journal of Thoracic Oncology.

97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

A. Tafreshi, Ying Cheng, B. Halmos, 2021 .

Venous Thromboembolism During Chemotherapy for Testicular Cancer: A Population-Based Study.

P. Bedard, M. Raphael, C. Booth, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%

Y. Shentu, A. Tafreshi, M. O'Brien, 2016 .

Imaging progression-free survival: How much does it matter to patients?

E. Eisenhauer, M. Brundage, C. Booth, 2018, Journal of Clinical Oncology.

Small Cell Lung Cancer in Light/Never Smokers - A Role for Molecular Testing?

A. Robinson, Tao Wang, G. Moffat, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

A. Tafreshi, Ying Cheng, B. Halmos, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407

A. Tafreshi, Ying Cheng, B. Halmos, 2019, Annals of Oncology.

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2

Gregory Riely, S. Temin, P. Ellis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Why "Reply All" Can Push All the Wrong Buttons.

M. Clemons, A. Robinson, A. Joy, 2019, The oncologist.

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2

Erin L. Schenk, Nofisat Ismaila, L. Sequist, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2

Nofisat Ismaila, Gregory Riely, I. Jaiyesimi, 2023, Journal of Clinical Oncology.

Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.

E. Eisenhauer, C. Booth, A. Robinson, 2014, European journal of cancer.

Patients’ attitudes and preferences toward delayed disease progression in the absence of improved survival

E. Eisenhauer, C. Booth, J. Galica, 2023, Journal of the National Cancer Institute.

Correlation between different carboplatin dosing patterns and its toxicity analysis in patients with advanced lung cancers: A retrospective study

A. Robinson, A. Kartolo, 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non–small cell lung cancer (NSCLC): KEYNOTE-867.

G. Giaccone, M. Ahn, H. Borghaei, 2022, Journal of Clinical Oncology.

Population kinetics of progression free survival (PFS).

M. Clemons, D. Bossé, A. Ocaña, 2019, Journal of Clinical Oncology.

Guideline for referral of patients with suspected lung cancer by family physicians and other primary care providers.

R. Zeldin, R. Skrastins, Y. Ung, 2014, Canadian family physician Medecin de famille canadien.

Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?

A. Robinson, A. Kartolo, A. Fung, 2022, Future oncology.